Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Adeona Pharmaceuticals, a specialty pharmaceutical company, has received a notice of allowance from the Japanese patent office for patent application that covers claims relating to various heat shock protein sequences which are derived from dnaJ.
Subscribe to our email newsletter
Oral dnaJP1 is a 14 amino acid sequence delivered once daily to rheumatoid arthritis (RA patients). Oral dnaJP1 has completed a 160 patient double-blind, placebo controlled Phase II clinical trial in RA patients which was funded by a $5 million grant from the National Institute of Health.
Nicholas Stergis, Adeona’s CEO, said: “This notice of allowance provides further intellectual property protection for various analog molecules which are related to dnaJP1, our oral, once-daily therapy for the treatment of RA which has already completed a double-blind, placebo-controlled, Phase II clinical trial.
“Upon issuance, we will add this patent to our growing set of intellectual property which encompasses over 47 issued, pending US and international patents related to this novel technology.”